Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients

International Journal of Oncology

Volumn 38, Issue 4, 2011, Pages 955-962

  Ota, Daisuke ^a   Mimori, Koshi ^a   Yokobori, Takehiko ^a   Iwatsuki, Masaaki ^a   Kataoka, Akemi ^b   Masuda, Norikazu ^c   Ishii, Hideshi ^a   Ohno, Shinji ^b   Mori, Masaki ^d  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Disease free survival; miR 181a; miR 21; Programmed cell death protein 4

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; MICRORNA; MICRORNA 181A; MICRORNA 21; PROGESTERONE RECEPTOR; PROGRAMMED CELL DEATH PROTEIN 4; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOACCUMULATION; BONE MARROW; BONE MARROW BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EXTRACTION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; BONE MARROW; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA INTERFERENCE; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79952320057     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.926     Document Type: Article

References (41)

1. Berger U, Bettelheim R, Mansi JL, Easton D, Coombes RC and Neville AM: The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol 90: 1-6, 1988.
2. Morimoto T, Sasa M, Yamaguchi T, Kondo H, Akaiwa H and Sagara Y: Breast cancer screening by mammography in women aged under 50 years in Japan. Anticancer Res 20: 3689-3694, 2000. (Pubitemid 32002261)
3. Westlake S and Cooper N: Cancer incidence and mortality: trends in the United Kingdom and constituent countries, 1993 to 2004. Health Stat Q: 33-46, 2008.
4. Rosen PP, Groshen S, Saigo PE, Kinne DW and Hellman S: Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 7: 1239-1251, 1989. (Pubitemid 19220125)
5. Braun S, Cevatli BS, Assemi C, et al: Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 19: 1468-1475, 2001. (Pubitemid 32202555)
6. Braun S, Pantel K, Muller P, et al: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342: 525-533, 2000. (Pubitemid 30117892)
7. Braun S, Vogl FD, Naume B, et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793-802, 2005. (Pubitemid 41215488)
8. Cote RJ, Rosen PP, Lesser ML, Old LJ and Osborne MP: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9: 1749-1756, 1991.
9. Gaforio JJ, Serrano MJ, Sanchez-Rovira P, et al: Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 107: 984-990, 2003. (Pubitemid 37429841)
10. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N and Jager W: Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 19: 3669-3674, 2001. (Pubitemid 32786279)
11. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U and Coombes RC: Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 354: 197-202, 1999. (Pubitemid 29329158)
12. Masuda TA, Kataoka A, Ohno S, et al: Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. Int J Oncol 26: 721-730, 2005.
13. Quintela-Fandino M, Lopez JM, Hitt R, et al: Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J Clin Oncol 24: 3611-3618, 2006. (Pubitemid 46630534)
14. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20: 3404-3412, 2002.
15. Wang S, Aurora AB, Johnson BA, et al: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 15: 261-271, 2008.
16. Mimori K, Iwatsuki M, Yokobori T and Mori M: Important matters to identify robust markers for metastasis and recurrence in solid cancer. Ann Surg Oncol 16: 1070-1071, 2009.
17. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006 (Pubitemid 44629897)
18. Asangani IA, Rasheed SA, Nikolova DA, et al: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27: 2128-2136, 2008. (Pubitemid 351485639)
19. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283: 1026-1033, 2008.
20. Lu Z, Liu M, Stribinskis V, et al: MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27: 4373-4379, 2008. (Pubitemid 352010003)
21. Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350-359, 2008. (Pubitemid 351333899)
22. Goke R, Barth P, Schmidt A, Samans B and Lankat-Buttgereit B: Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol 287: C1541-C1546, 2004. (Pubitemid 39507671)
23. Shibahara K, Asano M, Ishida Y, Aoki T, Koike T and Honjo T: Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene 166: 297-301, 1995.
24. Nieves-Alicea R, Colburn NH, Simeone AM and Tari AM: Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinase-2 expression. Breast Cancer Res Treat 114: 203-209, 2008.
25. Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H and Afonja O: Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol Rep 18: 1387-1393, 2007.
26. Goldhirsch A, Glick JH, Gelber RD, Coates AS and Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19: 3817-3827, 2001. (Pubitemid 32880060)
27. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144, 2007.
28. Mori M, Mimori K, Inoue H, et al: Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 55: 3417-3420, 1995.
29. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K and Mori M: Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 62: 3819-3825, 2002. (Pubitemid 34728867)
30. Masuda TA, Inoue H, Nishida K, et al: Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin Cancer Res 9: 5693-5698, 2003. (Pubitemid 37499492)
31. Kip1. J Biol Chem 283: 29897-29903, 2008.
32. Cuesta R, Martinez-Sanchez A and Gebauer F: miR-181a regulates cap-dependent translation of p27(kip1) mRNA in myeloid cells. Mol Cell Biol 29: 2841-2851, 2009.
33. Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 8: 736-741, 2009.
34. Kaplan RN, Riba RD, Zacharoulis S, et al: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827, 2005. (Pubitemid 41753060)
35. Mimori K, Fukagawa T, Kosaka Y, et al: Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res 14: 2609-2616, 2008.
36. Gao D, Nolan DJ, Mellick AS, et al: Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319: 195-198, 2008.
37. Yan LX, Huang XF, Shao Q et al: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14: 2348-2360, 2008.
38. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006. (Pubitemid 43271657)
39. Mimori K, Kataoka A, Yamaguchi H, et al: Preoperative u-PAR gene expression in bone marrow indicates the potential power of recurrence in breast cancer cases. Ann Surg Oncol 16: 2035-2041, 2009.
40. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691, 2009.
41. Corso A, Ferretti E and Lazzarino M: Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology 10: 215-224, 2005. (Pubitemid 41801138)